-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 UTniKToEXEjLC3O2NaPRKaL8MA3E+pBP1DBAWK4Z9BM4x6iPKW0068hvoK/x8YPb
 dYeXWgefOKitc5nFvCaEvQ==

<SEC-DOCUMENT>0001104659-06-062382.txt : 20060921
<SEC-HEADER>0001104659-06-062382.hdr.sgml : 20060921
<ACCEPTANCE-DATETIME>20060921161945
ACCESSION NUMBER:		0001104659-06-062382
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20060920
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20060921
DATE AS OF CHANGE:		20060921

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AVANT IMMUNOTHERAPEUTICS INC
		CENTRAL INDEX KEY:			0000744218
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				133191702
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-15006
		FILM NUMBER:		061102385

	BUSINESS ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
		BUSINESS PHONE:		7814330771

	MAIL ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			021942725

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	T CELL SCIENCES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a06-20036_18k.htm
<DESCRIPTION>CURRENT REPORT OF MATERIAL EVENTS OR CORPORATE CHANGES
<TEXT>
<html>

<head>






</head>

<body lang="EN-US">

<div style="font-family:Times New Roman;">
 <div style="border:none;border-top:double windowtext 6.0pt;padding:0pt 0pt 0pt 0pt;"> <p style="border:none;margin:0pt 0pt .0001pt;padding:0pt;"><a name="scotch"></a></p> </div>

<p style="font-weight:bold;margin:0pt 0pt .0001pt;page-break-after:auto;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;">UNITED STATES<br>
SECURITIES AND EXCHANGE COMMISSION</font></b></p>

<p style="font-weight:bold;margin:0pt 0pt 6.0pt;page-break-after:auto;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">Washington, D.C. 20549</font></b></p>

<p style="font-weight:bold;margin:0pt 0pt 6.0pt;page-break-after:auto;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;">FORM 8-K</font></b></p>

<p style="font-weight:bold;margin:0pt 0pt .0001pt;page-break-after:auto;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;">CURRENT REPORT</font></b></p>

<p style="font-weight:bold;margin:0pt 0pt 6.0pt;page-break-after:auto;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;">Pursuant to Section 13 or 15(d) of the<br>
Securities Exchange Act of 1934</font></b></p>

<p style="margin:0pt 0pt 6.0pt;page-break-after:auto;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report (Date of earliest event reported): <b>September 20, 2006</b></font></p>

<p style="font-weight:bold;margin:0pt 0pt .0001pt;page-break-after:auto;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;">AVANT
IMMUNOTHERAPEUTICS, INC.</font></b></p>

<p style="margin:0pt 0pt 12.0pt;page-break-after:auto;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant as specified in charter)</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr style="page-break-inside:avoid;">
  <td width="33%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:33.74%;">
  <p align="center" style="font-size:10.0pt;margin:0pt 0pt .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b><!-- SET mrlNoTableShading --></p>
  </td>
  <td width="1%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:1.98%;">
  <p style="margin:0pt 0pt .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="28%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:28.76%;">
  <p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">0-15006</font></b></p>
  </td>
  <td width="1%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:1.98%;">
  <p style="margin:0pt 0pt .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="33%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:33.54%;">
  <p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13-3191702</font></b></p>
  </td>
 </tr>
 <tr style="page-break-inside:avoid;">
  <td width="33%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:33.74%;">
  <p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or other
  jurisdiction</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:1.98%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:28.76%;">
  <p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission file
  number)</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:1.98%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="33%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:33.54%;">
  <p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS employer</font></p>
  </td>
 </tr>
 <tr style="page-break-inside:avoid;">
  <td width="33%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:33.74%;">
  <p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">of
  incorporation)</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:1.98%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="28%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:28.76%;">
  <p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:1.98%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="33%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:33.54%;">
  <p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">identification
  no.)</font></p>
  </td>
 </tr>
</table>

<p style="line-height:1.0pt;margin:0pt 0pt 12.0pt;"><font size="1" face="Times New Roman">&nbsp;</font></p>

<p style="font-weight:bold;margin:0pt 0pt .0001pt;page-break-after:auto;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">119 Fourth Avenue<br>
Needham, Massachusetts&#160; 02494-2725</font></b></p>

<p style="margin:0pt 0pt 6.0pt;page-break-after:auto;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices) (Zip code)</font></p>

<p style="margin:0pt 0pt .0001pt;page-break-after:auto;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s
telephone number, including area code:</font></p>

<p style="font-weight:bold;margin:0pt 0pt 6.0pt;page-break-after:auto;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">(781) 433-0771</font></b></p>

<div style="line-height:9.0pt;margin:0pt 0pt 6.0pt;page-break-after:avoid;text-align:center;"><hr size="1" width="672" noshade color="black" align="center" style="width:504.0pt;"></div>

<p style="margin:0pt 0pt 12.0pt 20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:</font></p>

<p style="font-size:10.0pt;margin:0pt 0pt 12.0pt 20.0pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font>&nbsp;&nbsp; Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="font-size:10.0pt;margin:0pt 0pt 12.0pt 20.0pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font>&nbsp;&nbsp; Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font-size:10.0pt;margin:0pt 0pt 12.0pt 20.0pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font>&nbsp;&nbsp; Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))</p>

<p style="font-size:10.0pt;margin:0pt 0pt .0001pt 20.0pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font>&nbsp;&nbsp; Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))</p>


 <div style="border:none;border-bottom:double windowtext 6.0pt;padding:0pt 0pt 0pt 0pt;"> <p style="border:none;margin:0pt 0pt .0001pt;padding:0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p> </div>
</div><br><hr size="3" width="100%" noshade color="#010101" align="center">

<!-- SEQ.=1,FOLIO='',FILE='C:\fc\263202859876_D11088_1376292\20036-1-ba.htm',USER='jmsproofassembler',CD='Sep 20 20:29 2006' -->



<br clear="all" style="page-break-before:always;">

<div>
 <p style="margin:0pt 0pt .0001pt;text-align:center;"></p>

<p style="margin:0pt 0pt 12.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10.0pt;font-weight:bold;margin:0pt 0pt 12.0pt 10.0pt;page-break-after:avoid;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">Item&nbsp;7.01.</font></b><font face="Times New Roman">&nbsp;&nbsp; </font>Regulation
FD Disclosure.<a name="Item7_01_RegulationFdDisclosure__203201"></a></p>

<p style="font-style:italic;margin:0pt 0pt 12.0pt 10.0pt;page-break-after:avoid;text-indent:-10.0pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;">Rotarix&#174; Royalty
Payments</font></i></p>

<p style="font-family:Times New Roman;font-size:10.0pt;margin:0pt 0pt 12.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On September 20, 2006, AVANT Immunotherapeutics, Inc.
(the &#147;Company&#148;) announced that GlaxoSmithKline (&#147;GSK&#148;) paid royalties on GSK&#146;s
sales of Rotarix</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font>&#160;rotavirus vaccine in Australia and certain
European countries at the lower of two royalty rates under their 1997 license
agreement. GSK&#146;s said that its decision to pay the lower royalty rate (which is
70% of the full rate) is based upon GSK&#146;s assertion that Rotarix<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font>&#160;is
not covered by licensed patents in Australia and these European countries. The
Company is evaluating the legal analysis underlying GSK&#146;s assertion to better
understand why GSK believes its development of Rotarix<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font>&#160;takes the vaccine outside the scope of the
claims of these licensed patents. The Company is analyzing various options to
counter GSK&#146;s assertion and protect its rights.</p>

<p style="margin:0pt 0pt 12.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Item 7.01, including
a copy of the press release attached as Exhibit&nbsp;99.1 hereto, is intended
to be furnished and shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18
of the Securities Exchange Act of 1934 or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933 or the Exchange Act, except as expressly set
forth by specific reference in such filing.</font></p>

<p style="font-family:Times New Roman;font-size:10.0pt;font-weight:bold;margin:0pt 0pt 12.0pt 10.0pt;page-break-after:avoid;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">Item&nbsp;9.01.</font></b><font face="Times New Roman">&nbsp;&nbsp; </font>Financial
Statements and Exhibits.<a name="Item9_01_FinancialStatementsAndEx_203250"></a></p>

<p style="font-style:italic;margin:0pt 0pt 12.0pt 30.0pt;page-break-after:avoid;text-indent:-10.0pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&nbsp;Exhibits</font></i></p>

<p style="margin:0pt 0pt 12.0pt;text-indent:20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following exhibit relating to Item&nbsp;7.01 shall
be deemed to be furnished, and not filed:</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;font-family:Times New Roman;width:100.0%;">
 <tr style="page-break-inside:avoid;">
  <td width="16%" valign="bottom" style="padding:0pt .7pt 0pt 0pt;width:16.88%;">
  <p align="left" style="font-weight:bold;line-height:8.0pt;margin:0pt 0pt .0001pt;text-align:left;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;">&nbsp;</font></b></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0pt .7pt 0pt 0pt;width:1.98%;">
  <p style="font-weight:bold;line-height:8.0pt;margin:0pt 0pt .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;">&nbsp;</font></b></p>
  </td>
  <td width="74%" valign="bottom" style="padding:0pt .7pt 0pt 0pt;width:74.08%;">
  <p style="font-weight:bold;line-height:8.0pt;margin:0pt 0pt .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;">&nbsp;</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0pt .7pt 0pt 0pt;width:2.38%;">
  <p style="font-weight:bold;line-height:8.0pt;margin:0pt 0pt .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;">&nbsp;</font></b></p>
  </td>
  <td width="4%" valign="bottom" style="padding:0pt .7pt 0pt 0pt;width:4.68%;">
  <p style="font-weight:bold;line-height:8.0pt;margin:0pt 0pt .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr style="page-break-inside:avoid;">
  <td width="16%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0pt .7pt 0pt 0pt;width:16.88%;">
  <p align="left" style="font-size:8.0pt;font-weight:bold;line-height:8.0pt;margin:0pt 0pt .0001pt;text-align:left;"><!-- SET mrlNoTableShading -->Exhibit<br>
  Number</p>
  </td>
  <td width="1%" valign="bottom" style="padding:0pt .7pt 0pt 0pt;width:1.98%;">
  <p style="font-weight:bold;line-height:8.0pt;margin:0pt 0pt .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></b></p>
  </td>
  <td width="74%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0pt .7pt 0pt 0pt;width:74.08%;">
  <p style="font-weight:bold;line-height:8.0pt;margin:0pt 0pt .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;">Description of Exhibit</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0pt .7pt 0pt 0pt;width:2.38%;">
  <p style="font-weight:bold;line-height:8.0pt;margin:0pt 0pt .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></b></p>
  </td>
  <td width="4%" valign="bottom" style="padding:0pt .7pt 0pt 0pt;width:4.68%;">
  <p style="font-weight:bold;line-height:8.0pt;margin:0pt 0pt .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr style="page-break-inside:avoid;">
  <td width="16%" valign="top" style="border:none;padding:0pt .7pt 0pt 0pt;width:16.88%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:1.98%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="74%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:74.08%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AVANT Immunotherapeutics, Inc. Press Release, dated
  September 20, 2006</font></p>
  </td>
  <td width="2%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:2.38%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="4%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:4.68%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>


 <p style="font-size:10.0pt;margin:24.0pt 0pt .0001pt;text-align:center;"><font face="Times New Roman">2</font></p> <br><hr size="3" width="100%" noshade color="#010101" align="center">

<!-- SEQ.=1,FOLIO='2',FILE='C:\fc\263203314968_D11088_1376294\20036-1-ca.htm',USER='jmsproofassembler',CD='Sep 20 20:33 2006' -->
<br clear="all" style="page-break-before:always;">
 <p style="margin:0pt 0pt .0001pt;text-align:center;"></p>


<p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-weight:bold;margin:0pt 0pt 12.0pt;page-break-after:avoid;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIGNATURES<a name="Signatures_203715"></a></font></b></p>

<p style="margin:0pt 0pt 12.0pt;page-break-after:avoid;text-indent:20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized. </font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;font-family:Times New Roman;width:100.0%;">
 <tr style="page-break-inside:avoid;">
  <td width="41%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:41.66%;">
  <p style="margin:0pt 0pt .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="4%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:4.96%;">
  <p style="margin:0pt 0pt .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="53%" colspan="2" valign="top" style="padding:0pt .7pt 0pt 0pt;width:53.4%;">
  <p style="margin:0pt 0pt .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr style="page-break-inside:avoid;">
  <td width="41%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:41.66%;">
  <p style="font-size:10.0pt;margin:0pt 0pt .0001pt;"><!-- SET mrlNoTableShading --></p>
  </td>
  <td width="58%" colspan="3" valign="top" style="padding:0pt .7pt 0pt 0pt;width:58.34%;">
  <p style="margin:0pt 0pt .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AVANT
  IMMUNOTHERAPEUTICS, INC.</font></b></p>
  </td>
 </tr>
 <tr style="page-break-inside:avoid;">
  <td width="41%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:41.66%;">
  <p style="margin:0pt 0pt .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="4%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:4.96%;">
  <p style="margin:0pt 0pt .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="53%" colspan="2" valign="top" style="padding:0pt .7pt 0pt 0pt;width:53.4%;">
  <p style="margin:0pt 0pt .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
 </tr>
 <tr style="page-break-inside:avoid;">
  <td width="41%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:41.66%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dated: September
  21, 2006</font></p>
  </td>
  <td width="4%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:4.96%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>
  </td>
  <td width="53%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0pt .7pt 0pt 0pt;width:53.4%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Avery W.
  Catlin</font></p>
  </td>
 </tr>
 <tr style="page-break-inside:avoid;">
  <td width="41%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:41.66%;">
  <p style="margin:0pt 0pt .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="4%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:4.96%;">
  <p style="margin:0pt 0pt .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="53%" colspan="2" valign="top" style="border:none;padding:0pt .7pt 0pt 0pt;width:53.4%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Avery W. Catlin</font></p>
  </td>
 </tr>
 <tr style="page-break-inside:avoid;">
  <td width="41%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:41.66%;">
  <p style="margin:0pt 0pt .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="4%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:4.96%;">
  <p style="margin:0pt 0pt .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="6%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:6.94%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>
  </td>
  <td width="46%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:46.44%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Senior Vice
  President and</font></p>
  </td>
 </tr>
 <tr style="page-break-inside:avoid;">
  <td width="41%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:41.66%;">
  <p style="margin:0pt 0pt .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="4%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:4.96%;">
  <p style="margin:0pt 0pt .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="6%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:6.94%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="46%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:46.44%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief Financial
  Officer</font></p>
  </td>
 </tr>
</table>

<p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>


 <p style="font-size:10.0pt;margin:24.0pt 0pt .0001pt;text-align:center;"><font face="Times New Roman">3</font></p> <br><hr size="3" width="100%" noshade color="#010101" align="center">

<!-- SEQ.=1,FOLIO='3',FILE='C:\fc\263203314968_D11088_1376294\20036-1-ca.htm',USER='jmsproofassembler',CD='Sep 20 20:33 2006' -->
<br clear="all" style="page-break-before:always;">
 <p style="margin:0pt 0pt .0001pt;text-align:center;"></p>


<p style="margin:0pt 0pt 12.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-weight:bold;margin:0pt 0pt 12.0pt;page-break-after:avoid;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">EXHIBIT INDEX<a name="ExhibitIndex_204224"></a></font></b></p>

<p style="margin:0pt 0pt 12.0pt;page-break-after:avoid;text-indent:20.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following
designated exhibit is filed herewith: </font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;font-family:Times New Roman;width:100.0%;">
 <tr style="page-break-inside:avoid;">
  <td width="20%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0pt .7pt 0pt 0pt;width:20.82%;">
  <p style="font-size:10.0pt;margin:0pt 0pt .0001pt;"><!-- SET mrlNoTableShading --><b>Exhibit<br>
  Number</b></p>
  </td>
  <td width="1%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:1.98%;">
  <p style="margin:0pt 0pt .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="77%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0pt .7pt 0pt 0pt;width:77.18%;">
  <p align="center" style="margin:0pt 0pt .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Description
  of Exhibit</font></b></p>
  </td>
 </tr>
 <tr style="page-break-inside:avoid;">
  <td width="20%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:20.82%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:1.98%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="77%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:77.18%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AVANT Immunotherapeutics, Inc. Press Release, dated
  September 20, 2006</font></p>
  </td>
 </tr>
</table>

<p style="margin:0pt 0pt 12.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>


 <p style="font-size:10.0pt;margin:24.0pt 0pt .0001pt;text-align:center;"><font face="Times New Roman">4</font></p>
</div><br><hr size="3" width="100%" noshade color="#010101" align="center">

<!-- SEQ.=1,FOLIO='4',FILE='C:\fc\263203314968_D11088_1376294\20036-1-ca.htm',USER='jmsproofassembler',CD='Sep 20 20:33 2006' -->


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a06-20036_1ex99d1.htm
<DESCRIPTION>EX-99
<TEXT>
<html>

<head>






</head>

<body lang="EN-US">

<div>
 <p style="margin:0pt 0pt .0001pt;text-align:center;"></p>

<p style="margin:0pt 0pt 12.0pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="right" style="font-weight:bold;margin:0pt 0pt 12.0pt 10.0pt;page-break-after:avoid;text-align:right;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exhibit 99.1<a name="Exhibit99_1_205825"></a></font></b></p>

<h1 align="center" style="font-weight:normal;margin:0pt 0pt 12.0pt;page-break-after:auto;text-align:center;"><font size="2" face="Times New Roman"><img width="332" height="63" src="g200361kai001.gif"></font></h1>

<p style="margin:0pt 0pt 12.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FOR IMMEDIATE RELEASE/September 20, 2006</font></b></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;font-family:Times New Roman;width:100.0%;">
 <tr style="page-break-inside:avoid;">
  <td width="35%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:35.66%;">
  <p style="font-size:10.0pt;margin:0pt 0pt .0001pt;"><!-- SET mrlNoTableShading -->Una S. Ryan, Ph.D.</p>
  </td>
  <td width="1%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:1.98%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="33%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:33.68%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Avery W. Catlin</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:1.98%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="26%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:26.7%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For Media:</font></p>
  </td>
 </tr>
 <tr style="page-break-inside:avoid;">
  <td width="35%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:35.66%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President and CEO</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:1.98%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="33%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:33.68%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief Financial Officer</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:1.98%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="26%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:26.7%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Joan Kureczka</font></p>
  </td>
 </tr>
 <tr style="page-break-inside:avoid;">
  <td width="35%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:35.66%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AVANT Immunotherapeutics, Inc.</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:1.98%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="33%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:33.68%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AVANT Immunotherapeutics, Inc.</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:1.98%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="26%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:26.7%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Kureczka/Martin Associates</font></p>
  </td>
 </tr>
 <tr style="page-break-inside:avoid;">
  <td width="35%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:35.66%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(781) 433-0771</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:1.98%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="33%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:33.68%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(781) 433-0771</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:1.98%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="26%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:26.7%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(415) 821-2413</font></p>
  </td>
 </tr>
 <tr style="page-break-inside:avoid;">
  <td width="35%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:35.66%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:1.98%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="33%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:33.68%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">info@avantimmune.com</font></p>
  </td>
  <td width="1%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:1.98%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="26%" valign="top" style="padding:0pt .7pt 0pt 0pt;width:26.7%;">
  <p style="margin:0pt 0pt .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">jkureczka@comcast.net</font></p>
  </td>
 </tr>
</table>

<p style="line-height:1.0pt;margin:0pt 0pt 12.0pt;"><font size="1" face="Times New Roman">&nbsp;</font></p>

<p align="center" style="font-family:Times New Roman;margin:0pt 18.0pt 12.0pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">LATEST
GSK REPORT ON SALES OF ROTARIX</font></b><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">&#160;EVIDENCES<br>
DISAGREEMENT ON ROYALTY RATE IN PATENT COUNTRIES</font></b></p>

<p style="font-family:Times New Roman;font-size:10.0pt;margin:0pt 0pt 12.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NEEDHAM,
MA (September 20, 2006):&#160; </font></b>AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN)
today announced that GlaxoSmithKline (GSK) paid royalties on GSK&#146;s sales of
Rotarix<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font>&#160;rotavirus vaccine in Australia and certain
European countries at the lower of two royalty rates under their 1997 license
agreement. GSK&#146;s decision to pay the lower royalty rate (which is 70% of the
full rate) is based upon GSK&#146;s assertion that Rotarix<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font>&#160;is not covered by the patents GSK licensed
from AVANT in Australia and these certain European countries. While GSK has
shared with AVANT the reasoning underlying its position in general terms, AVANT
continues to evaluate GSK&#146;s legal analysis underlying the assertion that its
development of Rotarix<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font>&#160;takes
the vaccine outside the scope of the claims of these licensed patents.</p>

<p style="font-family:Times New Roman;font-size:10.0pt;margin:0pt 0pt 12.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;We
are presently analyzing various options to counter GSK&#146;s assertion and protect
AVANT&#146;s rights. Although we have sold the bulk of AVANT&#146;s royalties from sales
of Rotarix</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font>&#160;to
Paul Royalty Fund II, L.P. and only retain a residual interest, we are of
course disappointed in this news. We maintain an open channel with GSK, which
has been one of AVANT&#146;s long-standing strategic partners, and our advisors are
hard at work evaluating what we have learned from GSK to date. At the same
time, we are determined to take all available steps to enforce our rights under
our license agreement with GSK, both regarding the recent sales in Australia
and Europe and future sales in the other countries in which we hold patents,&#148;
said Una S. Ryan, Ph.D., AVANT President and Chief Executive Officer.</p>

<p style="font-family:Times New Roman;font-size:10.0pt;margin:0pt 0pt 12.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In
May 2005, AVANT sold an interest in the royalties payable to AVANT by GSK on
worldwide sales of Rotarix</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font>&#160;to Paul Royalty Fund II, L.P. (PRF) for up to
$61 million. To date, PRF has paid AVANT $50 million. It is AVANT&#146;s view that
the $50 million already paid to AVANT by PRF and the potential $11 million in
additional milestone payments are not affected by this development.</p>

<p style="font-family:Times New Roman;font-size:10.0pt;margin:0pt 0pt 12.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If
AVANT is unable to reverse GSK&#146;s assertion that royalties are payable at the
lower rate, the value of AVANT&#146;s residual interest in Rotarix</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font>&#160;royalties under its agreement
with PRF would be adversely affected. In light of GSK&#146;s position, the royalties
to which PRF is entitled will no longer be limited by a</p>

<p align="center" style="margin:0pt 0pt 12.0pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">-more-</font></p>

<div style="line-height:9.0pt;margin:0pt 0pt .0001pt;page-break-after:avoid;text-align:center;"><hr size="1" width="672" noshade color="black" align="center" style="width:504.0pt;"></div>

<p align="center" style="margin:0pt 0pt 12.0pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:9.0pt;font-weight:bold;">119 FOURTH
AVENUE &#160;NEEDHAM, MA 02194-2725 USA &#160;781-433-0771 &#160;FAX 781-433-0262 &#160;www.avantimmune.com</font></b></p>

<br><hr size="3" width="100%" noshade color="#010101" align="center">

<!-- SEQ.=1,FOLIO='',FILE='C:\fc\263204031280_D11088_1376312\20036-1-ka.htm',USER='jmsproofassembler',CD='Sep 20 20:40 2006' -->
<br clear="all" style="page-break-before:always;">
 <p style="margin:0pt 0pt .0001pt;text-align:center;"></p>


<p style="margin:0pt 0pt 12.0pt;"><b><font size="1" face="Times New Roman" style="font-size:9.0pt;font-weight:bold;">&nbsp;</font></b></p>

<p style="font-family:Times New Roman;font-size:10.0pt;margin:0pt 0pt 12.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Latest GSK Report on Sales of Rotarix</font></b><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><b>&#160;Evidences Disagreement on Royalty Rate in
Patent Countries<br>
</b>September 20, 2006<b><br>
</b>Page <font face="Times New Roman">2</font></p>

<p style="font-family:Times New Roman;font-size:10.0pt;margin:0pt 0pt 12.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$27.5
million annual threshold, which AVANT projected may have been reached in later
years as sales of Rotarix</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font>&#160;increase. Irrespective of GSK&#146;s position,
AVANT will still retain essentially all of the royalties on worldwide sales of
Rotarix<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font>&#160;once
PRF receives 2.45 times the aggregate cash payments it makes to AVANT, though
the amount of such residual royalties will be lower if GSK&#146;s position stands. Further
information regarding the terms of AVANT&#146;s sale of the Rotarix<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font>&#160;royalty interest is available in
its prior public announcements and securities filings.</p>

<p style="margin:0pt 0pt 12.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About
AVANT Immunotherapeutics, Inc.</font></b></p>

<p style="line-height:normal;margin:0pt 0pt 12.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AVANT
Immunotherapeutics, Inc. discovers and develops innovative vaccines and
therapeutics that harness the human immune system to prevent and treat disease.
Six of AVANT&#146;s products are in clinical development, including a treatment to
reduce complement-mediated tissue damage associated with cardiac bypass surgery
and a novel vaccine for cholesterol management. AVANT is also developing a
pipeline of bacteria-fighting products for biodefense, travelers&#146; vaccines, and
global health needs based on AVANT&#146;S rapid-protecting, single-dose, oral and
temperature stable vaccine technology.</font></p>

<p style="margin:0pt 0pt 12.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Additional
information on AVANT Immunotherapeutics, Inc. can be obtained through our site
on the World Wide Web: http://www.avantimmune.com.</font></p>

<p style="font-family:Times New Roman;font-size:10.0pt;margin:0pt 0pt 12.0pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Safe Harbor Statement Under the Private Securities Litigation Reform
Act of 1995: </font></i></b><i>This
release includes forward-looking statements that are subject to a variety of
risks and uncertainties and reflect AVANT&#146;s current views with respect to
future events. There are a umber of important factors that could cause the
actual events to differ materially from those expressed in any forward-looking
statement made by AVANT. These factors include, but are not limited to: (1) the
interpretation and application intellectual property and patent laws in the
United States and in several foreign jurisdictions as they relate to Rotarix</i><i><font face="Symbol" style="font-style:italic;">&#210;</font></i><i>; (2) the process of obtaining regulatory approval for the sale of
Rotarix</i><i><font face="Symbol" style="font-style:italic;">&#210;</font></i><i> in major commercial markets, as
well as the timing and success of worldwide commercialization of Rotarix</i><i><font face="Symbol" style="font-style:italic;">&#210;</font></i><i> by our partner, GSK; (3) GSK&#146;s strategy and business plans to launch
and supply Rotarix</i><i><font face="Symbol" style="font-style:italic;">&#210;</font></i><i>
worldwide, including in the U.S. and other major markets;</i><i> (4) our ability to obtain
substantial additional funding; (4) AVANT&#146;s expectations regarding cash
balances, anticipated royalty payments and expenses, including infrastructure
expenses; and (5) other factors detailed from time to time in filings with the
Securities and Exchange Commission. You should carefully review all of these
factors, and you should be aware that there may be other factors that could
cause these differences. These forward-looking statements were based on
information, plans and estimates at the date of this release, and we do not
promise to update any forward-looking statements to reflect changes in
underlying assumptions or factors, new information, future events or other
changes.</i></p>

<p style="margin:0pt 0pt 12.0pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">&nbsp;</font></i></p>

<p align="center" style="margin:0pt 0pt 12.0pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">####</font></i></p>

</div><br><hr size="3" width="100%" noshade color="#010101" align="center">

<!-- SEQ.=1,FOLIO='',FILE='C:\fc\263204031280_D11088_1376312\20036-1-ka.htm',USER='jmsproofassembler',CD='Sep 20 20:40 2006' -->


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g200361kai001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g200361kai001.gif
M1TE&.#=A3`$_`'<``"'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"P`
M````3`$_`(<````"`@('!P<#`P,)"0D/#P\>'AX("`@6%A8%!04!`0$='1T+
M"PL;&QL3$Q,*"@H2$A(8&!@-#0T$!`07%Q<<'!P,#`P&!@84%!0.#@X1$1$?
M'Q\5%149&1D0$!`:&AHF)B8W-S<M+2TX.#@C(R,H*"@J*BH]/3TO+R\R,C(_
M/S\G)R<I*2DE)24Y.3DN+BXP,#`B(B(Z.CHK*RLQ,3$A(2$@("`S,S,^/CX\
M/#PV-C8T-#0L+"P[.SLD)"0U-35#0T-04%!>7EY145%%14575U=<7%Q-34U2
M4E)965E;6UM&1D9:6EI$1$1"0D)!04%45%1`0$!)24E5555,3$Q(2$A'1T=8
M6%A?7U]=75U65E9+2TM34U-*2DI.3DY/3T][>WML;&QH:&AO;V]@8&!S<W-R
M<G)I:6EU=75Q<7%J:FID9&1M;6UK:VMG9V=P<'!N;FY_?W]B8F)]?7UE965Z
M>GIC8V-W=W=\?'QT='1Y>7EX>'AF9F9V=G9A86%^?GZ#@X.=G9V+BXN2DI*7
MEY>%A863DY.9F9F$A(28F)B1D9&;FYN4E)2,C(R(B(B/CX^-C8V'AX>.CHZ!
M@8&)B8F0D)"5E96<G)R&AH:*BHJ"@H*>GIZ6EI:?GY^`@(":FIJHJ*BYN;FI
MJ:FXN+BBHJ*^OKZEI:6JJJJ\O+RSL[.MK:VCHZ._O[^@H*"LK*RAH:&NKJZR
MLK*]O;V[N[NKJZNTM+2FIJ:DI*2WM[>ZNKJGIZ>OKZ^VMK:UM;6QL;&PL+##
MP\/!P<'>WM[+R\O0T-#`P,#;V]O"PL+9V=G,S,S5U=71T='$Q,36UM;(R,C*
MRLK7U]??W]_2TM+&QL;.SL[%Q<73T]/<W-S:VMK=W=W8V-C'Q\?-S<W)R<G4
MU-3/S\_^_O[KZ^O\_/S]_?W[^_OZ^OKS\_/IZ>GV]O;DY.3T]/3HZ.CP\/#M
M[>WFYN;R\O+CX^/U]?7N[N[GY^?Q\?'L[.SAX>'@X.#O[^_EY>7JZNKBXN+W
M]_?Y^?GX^/C___\(_P#!"1Q(L.#`?Z`"`%C(4`"P?P8C@OL7#@3#BP``091H
M\)\X(!@9!AFWD>-!,"$O"OE7TF3!?Z$&I"00K"5'B$-2`@@#\9\HG4"#IAPP
MRJ;+HTB3*EW*M.G2?^2(Z!1C].88G2'*58WX3U@!G:2V=C0G(JB!<V)OQM0Y
M`EU:@3AU\ISX4ZC=H$3?.MW+MZ]?OO^&'=")`&W2?Z5T)B"F%VX@PND:3RPF
M$Z@"49()PJR<4I#>N"GG^KQ+>FC1OZA3JU[-%:5.!6$/J[.8<E!F,CJ+/"UC
MUPA+IIN!&ECW%G1(T75+*P>0E[7SY]!EDP@*A.1A,SJ/3#SZC]T"G:8D__]#
M5\(N@G:9X:X%>J8XN)RA>R9?3KIY]/OXH_\[)92!,?&H*!12`^Y\=HR`&#E@
M&%+_I*+`782D-]%Z.CWPD$G&880<?<K9E]^'(/Z%A%V>R6:"3JI\AH9.2?R6
ME!*D+6&=4L$%=8(Z8F5XD6BK<*A<*A*&*&2(_Q@#@5THN'58&CJE41PZ*:04
M`&:'G1,!:1(@DUZ-045XTWMR]93,&626:>89:JSQ54HJL''FF6TH$^20=-[W
M3R%W)7",>*Q,D%()[Z3USS(2I`1"H(?Q5YHA6U((%`7P;*4C0W--Q-*EF%X*
MS@HZM9+IIR[6*>JH$\53%D80&!"2&^*9PT)*"3#_(Z@A.KTAWC],*$>$.)EQ
M&10:DH(9WT&@8OI."SH=4BRFI#9;)V((,@1''"%5((]X@.B$2(["8A0`*N+-
MTX!R%C33JZ-`'>!,59,N5"EW]"";4B)S.FOO<__($=($SR1S`48*N"(>-(.%
M1,1V7-5S94@L(,K@*SH9X().BIS+F5!-S*A9MQJ*%Z].]-XK\JC_V(-!2"^4
M$P^G&`T1*H;BG)!2`=%("DNT#-EZ&#A.3&6*3D^\C"&Z02UB5+L[>2QO2"&/
M[+20_S"2TAPLT1%2!O>(UPC(DO(64@"LB(>,!3K%@H\#*3T@YV%$`[4`/C8A
M_:Y+_WP\;[U/Y_U4.2!A_U0N2[&DY(AXTCR0DF]<H0-#2BLHR>`C.E50SS]0
MZ%2'>&UKT$1*E[_$\8Y*<ZWWZ-#],\W%"U7'DCPQA"2#QAB2$T5*&X1S].DI
ME2'>.%*E9`=+I.@$@^-TMXV!+-]AQ(`T+<D=^MVD1[_:/V&DQ,A&_X@14@*R
MB`>)E+,<'4E*$X1]6#.&IT0+2_D@`*NL#+9=0#V2I"2%QLX?9C?3>$OO/USY
M&!=&.*`/[-4B)6P0CS(8D)([Q&T<?</(#,PA'CSH1`-98\D4=.+`^*%N(078
MASIHD)+P'.1SE'H>__['0J?\HQ4I:1'VZ%&#D+2`>##KF>O(T;Q[<"`E>1"/
MXO]T0H7?_,,6.GD!#B7B*X;0;#0VG`?V4.@N%6*D:2W,(G?`4864V*)Y9PC)
M9;PW$VHT[Q;DJ\EACN&GE`0">^U8VD4&4(S/R*]FXPA"2L`P1?@<QXH7P:(6
M!\F59?P+(S98$%QP\<$BB(T`*6E$\]R0DA?$0SQZT(D#A%$2ZNED#W;\(`">
M^`]J'`DC&%A&3ZB8-/W),9#](Z33_K&BD.A,,^VP04@@\!\&C>,)*1G"C/Z!
MCQJ&)(B'X<>I0G*$<6AF%CJ9`3^*<\>>W"$E4]"4'SOF2M')\IMPH<>KO`4N
MSU4N))(0CR)2HH$"PB47#\+(!.#'H&K@C"$E.H@Y7KG_$`704RVB?.)$\C$=
M@*TO?PS:WQ5C"4XB+>MF(;G!-$&EBY0X@5D8:D:A`+8+[-4A)3C@X6&T-Q-K
MQ.T-.N$#-0-:,[C`,"0KH`="X<7/A0BRH:,S!S_*40YQ@&,<_5#9YD(R"7Z8
MXZA(-8<ZKI&!E.1"'.(@!]W$T3N,D*$GY<A!2B`A'GU40"<GT,I+0G%/`%1`
MD5RI)ES$`<R0X&&F=%,H+'$J/4J(80I3H((*G,"',[Q!"E:00A"&<(0J2*$.
MD!`$)2+AB$@XUK%#P(%D):L"(*#A#$38$]TJD1(64/`?RDC?12RP-@:I`BB5
M*)8_9J`3@0V-I9T,AF@9(@%L__QCFZ#K)O3H2CIV7(,8UL"%(0A!B3HX80A,
M.(,E#!$+:P#C&=A`1CW\T0]RL`,?V"W'.+9+DG_,(PY7.(4ZN&,/"FROCO^X
M1$J>(%+N_`,+.LD`-?KAC_K:M[HH34D6A*89M1Z$DB%1PC]&-*R$UA0`-^7M
M+$$%#AT`[`%ML`4D('&(2E!B$5H!%3L>41Z!->8?,`H))B"BA90\0CSA^&I*
M!+"#&[CXQ2[>0>M2T@!W,M&_<)F'BB^B`%[DJL`T]::"__>/7-PS`_GX1W75
M<8PB.**]EUJ'()9&!_&``J3@P(<NE0<-\>@BGCX2(Y5N#-N79"(E/(@@-PTL
MY"%+[_\?`,8($S`%C#&$#WO_0(8F"LJ0#D2*0>$P+T8*<`ZB-8%7#/K'$L(,
M%,21>68MU0P_'+R],.EVA6Y^<SHZD))>L(0?BRA#-HSXCVLXX@P,Q#1W0HR1
M5_3!Q.(1QD89'9((3.[1(1'H2V;1QKO,#4-R94B",_VT?U@B)36`&S+>$(CM
ML$0?I*@#+/A1XI!4H;UT$P68&;*%*/E-2X>1&JW!(RD<:Z;:O@:DL!E*;#N-
M0ZLA<:`OQ#`-3,W#%)C@13]8,@A8/>/#Y]@Q0S*P[84T@;]<$8<5QJT3*2"Z
M(^8^B#$T0)I?WR38-F5WNTN7C()=Y`&E8$0="LB2>6R"$KS_\(<1C3'KBV@D
MT5D@C6T.8XRF,CPD$M`&NR)^D%>G^](+W;C>_@&'M/&AHRP)!R?$((J)'F0<
M70Q)"J9IVKMD0.>'X6Q\/5"`KGO]ZUWW0,LQ4K&TEIDK\BB/72S.1(PC6.-"
MGUX[!,X0+G3Y'^Y(!!L6<:VCT2HEO``XW5.RA(?3;=(ZH<$^UC&/QCO^\8T_
MQSYVH).,'8WG!_GRVM6=\;C/<A,AN<"(_Y&/08RA%>B1%%-3PJK#X$8HUSO,
M-A*@DTPL"U1X2LG?('YVKOQCJ$%A.U?</FS/B^H?4,=("AY2CT&<H16!$M0_
M%AX2"A2(0;00R@-L>Q@+LI.3A^&&_P`H=OG><V4;AP2*\#M"?+@;OR\L60;9
M&'(&^G*"#9U@!\([D@B==.+#\B!`.G$%--(/BY,25``[&%(./:`33J"`301"
MD7833!)\G/=V[^<L+/%1"X$!NI!>3]`*,M4KQN`!*0$$V(8AKY<2"G`*XM$-
M904`RO(4B*`3#`!N_65^7+$.`@AD<75@Q9>!1/(.!14$R1`,70``V20A'B$%
M*<$`WO!AIZ43$6!CW'$5*2$!$\@@TI!^&'%B8Z6#7'%LZG>!02B$^0$XH]0'
MHN`%#.%:3?$/F*`3@\,@\L`R(8$%^_<2N:030;"'"3<Q*=$#5'<0F/<2Y2"(
M/@AL0.A^:/_X%-\`!1)P!`W($#8@4R[T#3JQ`9C('3X7$BYX&$BD$^L3AW.H
M$Z=Q$+WP&J/&(,P`%+]S&.RP,"$Q<X\X)/^P#CTP`5+0")[@"((@"(Y0"_7R
M#^60!E[P!<JXC$&`@W3S#4BPC,N(!;9S&(=P!-*XC&2@?W&H#-&8C5]P!(&G
M&=0P!.#X!4E`'(D&!LF8C4?P">(1#V=PCEZ0BK<8(K4``TA@"?KW*?"W+,YT
M&,L"'`/I0K?7$04ID`FID`QVCT*2!]T#B'MQD#32D!59+(!!D9JQD(F&D4_!
MD0Z)'YH2DB19DE!CDBB9DBKY+"Z"499":J&"42/YDG`1DT+CDB__Z8\SR2P%
M:9'$<I/^6)-!N9,PR6`SF9-Q@Y,WT9(VV3Q*N9(W$9`(@V=',T4(\U,%(94_
M%2KX\VQPTY)(>95.N9%'V1,PN9%7*9290I:K)!"PTY5K:2D_B0_YP"M4^0[Y
MH'(2B95PT5T#T97BD`_]Z(A"]P_\<`9/D%KJD`5`T`2>4C)4T`1.``HPT01`
M\`49%`A.T`1!4$"O$`6:8"FW\`2>8(QA\`1AP$/_L`A/D`5N\0_^8`E'P`$V
M0`7_QQ*3@`-1X`1$``11T";_4`U-@`43-0U$4`4FE0M-T`1/$`7.B0,58PY)
M()G.^01>$`N=Q`R]>3D]X0Y'()DJ\`1+_S`):/$/@``$ONF<*A`$.,()3^`'
M$W4(3R`$X``*NOD$1$`$3Z`"47`,^$`%77`-EP(+3&`##X`#CG`M$_$,<M`"
M!'`#<O!O&-(*4:`1_H"8;V"7A/">$U4/F'`"!&`#2N`+>XF2_Z`.G**'[/!#
M`/`$)/%2`*`)J\D0X5$..+`0`;`/_[`'`+`%EV)!50";/+`0E\`25\$!@=(/
M&X018J`57)`2(_`/K@``$?!9L+`0=:1>(=$>\F""&'$!=007U0,`%B!%$V$,
M,<1#1Q`2'J!_VE,!G\4&`$`!X$`)K74."Y$,+`%Z_61P@3(,%,<<"Z$!PY`C
MKW8$X\$RK\`2;_]*0?2@`GT*``$0&U#)%?$0):Q"0PL1`0421@LQ.#`*!WAW
M,J,4*=0"!9>2+2[C#R&P$#40*:]6`Q3T&``@CJ%0;0(3#=1@#1]U`\GP#?^Q
M"P#0`AG&"P"0``\!,0<`"]X@#=)`#)&!#U_E!M[P#9TP+AWT#^^@=@"P"CV1
M#0PT!\K`"QO$`#I78B&PJ]*P#,K`0RBU`CCR#WD``"00#_I`#<MP"W[2"-+P
M#?0`#P\@`-]0)!1W`[Q`##P*`+8Q!_0:#-"@>;?$%0RK!>/A;2T@1>^*(YRE
M`&#P#<=P`P#@`?M0J9:*J75C3`E0#>.0`@/P(*#*$"$`#J&@`#)1`*;_"@"H
MRA*J"INMNA"V<DTUH`[CL#E$,%'C`*DZH)?IU:*8<J4QX`[LP`Y7AJS_`#$,
M8`^?(JT`($DLL04`8`8],0L!<`&J,@7.]`_@"@!A\0_!H``)8$8EM@1K^0\9
MRQ+S2@+1-RBT!R0LL0\!.["<)0%RPA)=D`%M\`]KF@-?V0N8``I:^1(36[$,
M`2SOB@X&B+.70@P8X`!12+(O<:D`D*DUQ$",<`\$@`)?\;("@``,D`^2H`!1
M8K/_<*JI"@"KVJHZT`$70`U_```UP`_[<#*>`A>+```.P(W_P`D`@`-B]0]7
M.@`8P`$(\!47D*S,`01(,`1!8`23H[55,`B*_S`'9/-_$V$'`+`#RHL!D8&V
MI.L/[,`'`&"N_U!B'#!8VDL)$U&W\DJO%#01W4![KO4/?BL`C&$$`'`"B%8W
MZ7`M6V-64S`)X"(HD0LE```#$B``TL"C*^`/Y\!IW@H7[N`.Y>"YGVNRFOH$
M!(`%/:($'P``+PL!(+$+17`!\"6[M,L2-7B[```'>-(%3%(#_3`-"P$D</&*
M$8")R;N\S7NEH6>]&#$`.JJU&$&Q+.$.[H,(Y?!5U\.^<[H"&[`06Z`5Z,80
M4L`2^GNW_?L/_PL``3S`C%$Y*$B5X*`.>>"E"P$"8<I$$QPE;]"[1O"NY3![
M`)"*3TFR_P"ZH@L`:O_0`C%`!PJ0"%_UL@[`HVY0`S`P/C8,`([$$GBBPWP@
M#Z_R';_K0P"PJ'`!>L?;$\K+O#UQI0TP"L5P#'-(M<K:"<'`"JP`#"JGM20@
M!5W`*2N@<__0(P#@";(P,2?`0VD[``(@`!G@!9$ROP"0`JA0#*Q0"MXP$5?!
M`J^Y(B20QFO<Q@'+&!L$!$;$#_5@#I8B#+^`"$/@)R$P43>YQSM1#R`P`*JR
MP>[`:5\$%_@@#U)5HB%YR"9<0W<P(AH@`<%P)2];`+]@`5\A!+0BNQ94QBP!
M7U_`LP`@!\XK(#40#^0`LEN@FO\`$A*ERDK<R@```I<"3;0<O[:3*5H;!RS_
M(;8`0*+2C!$$P#QIVPCUL`[$<2DEU@6@@E(VT,T`8`"(HL8`W!,#/+">```-
MD$$#5@!!Y`E!@-,[&K_E.<\`0+$43!40LQ"-TP]#*D/_X`P?\`'F(M`.2="A
M>[(`,`G?`P`H$+PN_$(`(`'5,*0`8`CJ);OC\P"?$`VUT,)(8)BMRM'_X+6^
M2T%:9P3?X`WPVZW8L\I+#``^$*^!\](74`BDT`JM$`CKHK6ER;8!H`#A<PYH
MXP)"H`13\"^VE[9OI"DL46(FL`FO(-JO$!D_H0!HD`VH4$-)VQ/A[-1_^P_:
M4"@]``S2,`</4J1/^LKW8`PCDB3UT`9KH$8'0<]4_\$/.@2O__!1%Q`)PE`,
ME%<!^G`-;K`&)%PJKW)5[&!>8!`*"Y$%[#`8&J&ET.`'"U$-4C,!.IH/)P(`
MAT0`18$.+P```J;&9$,!@>(/20@`"A!/1H`.![%./]"\_/$!\<K$=42K&.$'
M_R`/1P)*;)MQQS8!;?T/-XH"Y9`-"Q%[Q.*&(4&B\=!6Z6="$[$-"T&9$V$/
M"\$-+/%W%+X077!)U9`^`A!/MH$-"Y%:FG%-7C`>KT+BP6DX"T!!\D!IAQ0`
MM_`/LK`0[VV86'`#@Z,.0W`#A[`.*J`#MX`.2[`#85$+.J`"\]`*-V`%\N`*
M/P`$Y8D,1K`"$[``6E`4L/\I!S>P+2RA"3<P!)=THI-P`Q<@`3U0"/MV$*ZP
M`V(@4O]0##H`!:\)#"'0`XS1"R$0`CKP`SJ@`S<@2>_@!3<`C\3D!3O`!OU0
M!C=`!W99M3L`!.\P#U'P`QVUD6#P`ZK>ZC\P`O7V#^V0!X2.`%M0BG#A#3D0
M`J70$^L0!2>@)2S1"CD@`1F@`I2`(Q-Q#%-0`1-0`4O0";SB#E:@`#0.%X>0
M`GSD#V=."9?R!S>@!:_I#G70`A/0`5_@:8,B`SKPW@)!#OW@4^#`\#Y%#F(%
M\3]5#E(E#@WO$=5%+/0`#22W$11O*1M?D_R@#<*@F@6!\5+UEQ;/\MI5\3P5
M\PV%O_`S/Q$8WP_CP`_[UA)!Y4P\];@"@?$Q'_,!R1+X``WKVQ+C\/,$(?%%
M#Q79$`U^^9+GT`P?[Q&@%SXI[P\.'_(L,?*6(@_0($6_L?0CK/`C:=MGJ?9F
MZ91EV91LR5]OWTEL/Y1P/_="Z7L6&9=L299Q_Q(R&0T,@`9G[_<TF?<_V90!
#`0`[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
